plenti cmv puromycin destination vector Search Results


pad cmv v5 dest gateway vector  (New England Biolabs)
97
New England Biolabs pad cmv v5 dest gateway vector
Pad Cmv V5 Dest Gateway Vector, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/pmc06544051-230-7-14?v=New+England+Biolabs
Average 97 stars, based on 1 article reviews
pad cmv v5 dest gateway vector - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier
plenti cmv vectors  (Addgene inc)
96
Addgene inc plenti cmv vectors
Plenti Cmv Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/pm28447629__41586_2017_BFnature22083_MOESM147_ESM-3-6-10?v=Addgene+inc
Average 96 stars, based on 1 article reviews
plenti cmv vectors - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
ovcar8 cells nci nci60 recombinant dna plenti cmv mcs rfp svpuro vector addgene  (Addgene inc)
96
Addgene inc ovcar8 cells nci nci60 recombinant dna plenti cmv mcs rfp svpuro vector addgene
Ovcar8 Cells Nci Nci60 Recombinant Dna Plenti Cmv Mcs Rfp Svpuro Vector Addgene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/pm35880015-277-49-57?v=Addgene+inc
Average 96 stars, based on 1 article reviews
ovcar8 cells nci nci60 recombinant dna plenti cmv mcs rfp svpuro vector addgene - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
lentiviral expression vector plenti cmv hygro dest  (Addgene inc)
95
Addgene inc lentiviral expression vector plenti cmv hygro dest
Lentiviral Expression Vector Plenti Cmv Hygro Dest, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/pm36302844-254-21-28?v=Addgene+inc
Average 95 stars, based on 1 article reviews
lentiviral expression vector plenti cmv hygro dest - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
plenti hygro vector  (Addgene inc)
93
Addgene inc plenti hygro vector
Plenti Hygro Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/pmc07119369-162-17-20?v=Addgene+inc
Average 93 stars, based on 1 article reviews
plenti hygro vector - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
plenti cmv to neo vector  (Addgene inc)
93
Addgene inc plenti cmv to neo vector
Plenti Cmv To Neo Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/pmc03021997-320-2-11?v=Addgene+inc
Average 93 stars, based on 1 article reviews
plenti cmv to neo vector - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
plenti tetr blast mammalian expression plasmid  (Addgene inc)
93
Addgene inc plenti tetr blast mammalian expression plasmid
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Plenti Tetr Blast Mammalian Expression Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/pmc08893345-130-0-7?v=Addgene+inc
Average 93 stars, based on 1 article reviews
plenti tetr blast mammalian expression plasmid - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
cmv promoter  (Addgene inc)
96
Addgene inc cmv promoter
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Cmv Promoter, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/us10920196-169-19-26?v=Addgene+inc
Average 96 stars, based on 1 article reviews
cmv promoter - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
plko 1 puro vector  (Addgene inc)
94
Addgene inc plko 1 puro vector
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Plko 1 Puro Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/pmc09365569-30-1-17?v=Addgene+inc
Average 94 stars, based on 1 article reviews
plko 1 puro vector - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
destination vector plenticmv gfp dest  (Addgene inc)
93
Addgene inc destination vector plenticmv gfp dest
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Destination Vector Plenticmv Gfp Dest, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/bio_rxiv__2023__11__22__567682-179-13-18?v=Addgene+inc
Average 93 stars, based on 1 article reviews
destination vector plenticmv gfp dest - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
lentiviral expression vectors  (Addgene inc)
93
Addgene inc lentiviral expression vectors
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Lentiviral Expression Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/10__1091_slash_mbc__e15___09___0645-188-4-8?v=Addgene+inc
Average 93 stars, based on 1 article reviews
lentiviral expression vectors - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
generation plenti teton vector  (Addgene inc)
93
Addgene inc generation plenti teton vector
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Generation Plenti Teton Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+puromycin+destination+vector/morgan_charles_william__2015__molecular_insights_from_protein_cellular_engineering_conditional_proteolysis_to_phosphorylation-683-9-14?v=Addgene+inc
Average 93 stars, based on 1 article reviews
generation plenti teton vector - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

Image Search Results


(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 TetR STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.

Journal: Cell reports

Article Title: Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells

doi: 10.1016/j.celrep.2021.110236

Figure Lengend Snippet: (A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 TetR STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.

Article Snippet: pLENTI TetR BLAST mammalian expression plasmid , Addgene , Cat#17492.

Techniques: Expressing, Microarray, Western Blot, CRISPR, Live Cell Imaging, Micro-CT

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells

doi: 10.1016/j.celrep.2021.110236

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: pLENTI TetR BLAST mammalian expression plasmid , Addgene , Cat#17492.

Techniques: Virus, Microarray, Recombinant, Lysis, Protease Inhibitor, Membrane, Saline, Autoradiography, Plasmid Preparation, Control, BIA-KA, Reverse Transcription, Enzyme-linked Immunosorbent Assay, Expressing, Software, Mass Spectrometry, Targeted Proteomics, Real-time Polymerase Chain Reaction, Live Cell Imaging